Document Detail

A pilot study of the use of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography to assess the distribution of activated lymphocytes in patients with systemic lupus erythematosus.
MedLine Citation:
PMID:  15077306     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: The 2-[(18)F]-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) technique provides information on uptake and metabolism of glucose in various tissues. Compared with resting cells, activated lymphocytes take up radioactively labeled glucose analog at a higher rate, which makes it possible to identify lymphoid organs with higher concentrations of activated lymphocytes. This study was undertaken to compare the pattern of PET images and quantitative FDG uptake in lymphoid organs of patients with active systemic lupus erythematosus (SLE) versus patients with inactive SLE and to correlate these findings with peripheral blood lymphocyte phenotypes. METHODS: Ten patients with active SLE and 9 patients with inactive SLE were studied. FDG-PET images were obtained from the inguinal region to above the ear, starting at 60 minutes after injection of FDG. Standardized uptake values using lean body mass were determined over areas of interest. RESULTS: Both patients with active lupus and those with inactive lupus had increased FDG uptake in lymph nodes when compared with healthy volunteers, and there was no statistically significant difference between the 2 groups of lupus patients. Thymic uptake was demonstrated in 5 of 10 patients with active lupus compared with 0 of 9 patients with inactive disease. Three of the 5 patients with active SLE who were over 29 years of age had thymic uptake. Of the activation markers tested, only the CD3/CD71 population of cells was significantly different between the patient groups, with an increased percentage in the active disease group (P = 0.0247). CONCLUSION: Increased FDG uptake in lymph nodes of both patients with active SLE and patients with inactive SLE suggests that metabolic, and probably immunologic, activity is enhanced not only in active, but also in clinically quiescent, disease. The increased thymic uptake observed only in patients with active disease suggests that the thymus plays an important role during periods of disease activity.
Miroslawa Nowak; Jorge A Carrasquillo; Cheryl H Yarboro; Steven L Bacharach; Millie Whatley; Xavier Valencia; Kazuki Takada; Douglas G Brust; Gabor G Illei
Related Documents :
3839896 - The design and use of a charting system for automatic record keeping during extracorpor...
7306226 - Acetylator phenotype and metabolic disposition of isoniazid in japanese patients with s...
10713646 - Dermatomyositis and polymyositis associated with the antiphospholipid syndrome-a novel ...
22454896 - Purine and pyrimidine excretion in psoriasis: a comparison with healthy controls during...
12363386 - Decreased calcium-dependent constitutive nitric oxide synthase (cnos) activity in prefr...
17014506 - The kidney disease wasting: inflammation, oxidative stress, and diet-gene interaction.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Arthritis and rheumatism     Volume:  50     ISSN:  0004-3591     ISO Abbreviation:  Arthritis Rheum.     Publication Date:  2004 Apr 
Date Detail:
Created Date:  2004-04-12     Completed Date:  2004-05-11     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0370605     Medline TA:  Arthritis Rheum     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1233-8     Citation Subset:  AIM; IM    
National Institute of Arthritis and Musculoskeletal Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers
Fluorodeoxyglucose F18 / diagnostic use*
Lupus Erythematosus, Systemic / immunology*,  radionuclide imaging*
Lymphocytes / immunology,  radionuclide imaging*
Lymphoid Tissue / immunology,  radionuclide imaging
Middle Aged
Pilot Projects
Radiopharmaceuticals / diagnostic use*
Tomography, Emission-Computed / methods*
Reg. No./Substance:
0/Biological Markers; 0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis o...
Next Document:  Antibodies to microtubule-associated protein 2 in patients with neuropsychiatric systemic lupus eryt...